Click here to close now.


News Feed Item

Q3 Medical Devices Ltd: UKMMC Became The First Centre To Deploy Archimedes Biodegradable Biliary Stents In Asia

KUALA LUMPUR, Malaysia, March 24, 2014 /PRNewswire/ -- The Endoscopy Centre of UKM Medical Centre (UKMMC) is making history by successfully utilizing, first in Asia, a biodegradable stent on a 56 year old patient who presented acute cholangitis.

The novel biodegradable stent for biliary and pancreatic duct is a revolutionary new idea and it was made available by QualiMed Innovative Medizinprodukte GmbH, a Q3 Medical Devices Ltd, subsidiary, a well known innovative medical devices company from Germany.

The stent is made of well known polymers similar to the ones used in medical sutures. It remains in the biliary duct until the cholangitis is resolved, before it is slowly hydrolysed by the body. According to Dr. Hairol Othman, a consultant hepatobiliary and pancreas surgeon at UKMMC, a patient has to undergo another procedure to remove the stents, when using the conventional ones. 

The Archimedes device comes with three degradation times to accommodate the various disease states that require different indwelling times for treatment.  [Fast absorbing (weeks), medium absorbing (months), and a long last (closer to a half year)]  Unlike traditional plastic biliary stents that are used hundreds of thousands of times per year and have to be removed and/or exchanged routinely to relieve the Archimedes device can be used and implanted using the exact techniques applied with the existing technology with the added benefit of allowing the bile to flow on the outside of the devices as well as through the center helping to minimize the potential for post implant obstruction while eliminating the cost and risk associated with the removal procedures.  The elimination of removal procedures is expected to significantly reduce total procedure cost for the patients that are treated with the Archimedes device.  The device is for investigational purposes only and is not CE or FDA approved at this time.

Speaking after the successful surgery, Dr. Hairol said: "Archimedes biodegradable stents are a revolutionary new concept in the biliary and pancreatic duct drainage. They are easy to deploy and very convenient for the patients. They negate the need for a repeat ERCP, hence reducing patients' anxiety and inconvenience. Plus, they do incur only one cost compared to conventional stents."

The Endoscopy Centre of UKMMC has been chosen to participate in the multi-centre phase 1 clinical trial for the biodegradable stents in Asia.

Speaking on behalf of Q3 Medical and QualiMed Eric K Mangiardi, CEO of Q3 Medical, commented: "This is a significant milestone for the company as we continue to explore developments in the area of biodegradable implants, that will improve efficacy and eliminate cost for the patients and care givers that treat them. We are continuing our development in the areas of fully covered biodegradable esopahageal and balloon expandible biodegradable, covered and uncovered biodegradable biliary and peripheral vascular devices that will further the advancement and treatment options for patients and doctors globally." 

About Q3 Medical Devices Limited

Q3 Medical Devices Limited is an Irish based holding company with multiple operations in Germany and strong partnerships throughout Asia through its growing investor base, including China Pioneer Pharma Holdings Limited listed on the Hong Kong Exchange (1345). The holding and its companies are focused on the development, manufacturing and distribution of minimally invasive devices for the treatment of patients with cardiology, peripheral vascular and non-vascular diseases.

Q3 Medical Devices Limited was formed by a global group of entrepreneurs, manufactures, distributors, industry doctors and investors, focused on the development and acquisition of medical device businesses with annual revenues between 1-10 Million. The acquisitions are targeted in areas that expand the groups manufacturing base and capabilities,  resulting in the growth of its distribution channels and accelerating its products offering, focusing on the minimally invasive treatment of patients with cardiology, peripheral vascular and non-vascular diseases.

About QualiMed

QualiMed, a wholly owned subsidiary of Q3 Medical, was founded in 1997 in Winsen, Germany near Hamburg, where it develops, manufactures and sells implantable medical devices in the Cardiology, Peripheral Vascular, and Non Vascular areas. The innovations are focused in the areas of Biodegradable Products, Drug Device Combination Technologies, Catheter and Mechanical implant areas. Originally founded as an OEM, the company's products are now sold in over 50 countries worldwide through its OEM, Private Label, and Own Brand Networks. The company and its development partners have obtained CE and FDA approvals for more than 70 different products including 3 different drug eluting stents.

Forward Looking Statements

This announcement includes "forward-looking statements" which incorporates all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group´s present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to QualiMed's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements are valid at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

For more enquiries and/or photos of event, please contact

Q3 Medical Devices Ltd
Investor Relations
Tel: +353867827296

QualiMed Innovative Medizinprodukte GmbH
Investor Relations
Tel: +49(0)417165780 (main office)

UKM Medical Centre (UKMMC), Cheras
Ms. Normahani Md. Ramdani
Public Relations Officer
(Tel)        03-91455053/6313
(H/P)       019-3220884
(Fax)       03-91456640
(Email)    [email protected]
Department of Public Relations
UKM Medical Centre

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
We all know that data growth is exploding and storage budgets are shrinking. Instead of showing you charts on about how much data there is, in his General Session at 17th Cloud Expo, Scott Cleland, Senior Director of Product Marketing at HGST, showed how to capture all of your data in one place. After you have your data under control, you can then analyze it in one place, saving time and resources.
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi’s VP Business Development and Engineering, explored the IoT cloud-based platform technologies driving t...
As organizations shift towards IT-as-a-service models, the need for managing & protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection & E-Discovery of your data - whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise.
In recent years, at least 40% of companies using cloud applications have experienced data loss. One of the best prevention against cloud data loss is backing up your cloud data. In his General Session at 17th Cloud Expo, Sam McIntyre, Partner Enablement Specialist at eFolder, presented how organizations can use eFolder Cloudfinder to automate backups of cloud application data. He also demonstrated how easy it is to search and restore cloud application data using Cloudfinder.
The Internet of Things (IoT) is growing rapidly by extending current technologies, products and networks. By 2020, Cisco estimates there will be 50 billion connected devices. Gartner has forecast revenues of over $300 billion, just to IoT suppliers. Now is the time to figure out how you’ll make money – not just create innovative products. With hundreds of new products and companies jumping into the IoT fray every month, there’s no shortage of innovation. Despite this, McKinsey/VisionMobile data...
Internet of @ThingsExpo, taking place June 7-9, 2016 at Javits Center, New York City and Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 18th International @CloudExpo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo New York Call for Papers is now open.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York and Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty ...
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, rich desktop and tuned mobile experiences can now be created with a single codebase – without compromising functionality, performance or usability. In his session at DevOps Su...
As organizations realize the scope of the Internet of Things, gaining key insights from Big Data, through the use of advanced analytics, becomes crucial. However, IoT also creates the need for petabyte scale storage of data from millions of devices. A new type of Storage is required which seamlessly integrates robust data analytics with massive scale. These storage systems will act as “smart systems” provide in-place analytics that speed discovery and enable businesses to quickly derive meaningf...
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).